Related Experiment Video
Updated: Aug 15, 2026
10:26
Inducing Apical Periodontitis in Mice
Published on: August 6, 2019
Animal health pharmaceutical industry
Richard A Carnevale1, Thomas R Shryock
1Animal Health Institute, 1325 G Street Suite 700, Washington, DC 20005, USA. rcarnevale@ahi.org
Preventive Veterinary Medicine
|November 4, 2005
Summary
Animal health companies report antimicrobial ingredient sales. National usage data compilation is complex, so local programs are recommended for prudent antimicrobial use in animals.
Area of Science:
- Veterinary Pharmacology
- Animal Health Economics
- Food Safety Microbiology
Background:
- The animal health pharmaceutical industry voluntarily reports antimicrobial active ingredient volumes sold in the U.S.
- Regulatory requirements mandate reporting of finished product distribution data to the FDA for surveillance and pharmacovigilance.
- Antimicrobial usage data has potential applications in risk assessments, including evaluations of microbiological safety for food animal antimicrobials.
Purpose of the Study:
- To discuss the complexities and challenges in compiling national antimicrobial usage data in the U.S. animal health sector.
- To highlight the limitations of current data reporting for comprehensive usage analysis.
- To recommend alternative approaches for promoting prudent antimicrobial use.
Main Methods:
- Review of existing reporting practices for antimicrobial ingredients and finished products in the U.S. animal health industry.
- Identification of challenges hindering the compilation of national antimicrobial usage data, including confidentiality, auditing, and practice variations.
- Analysis of the relevance of reported volumes in the context of the U.S. animal population.
Main Results:
- While data on antimicrobial ingredient sales and product distribution exists, national usage data compilation is hindered by significant challenges.
- Factors such as confidentiality, variations in field practices, population dynamics, and generic usage complicate accurate national data aggregation.
- Reported volumes of antimicrobials require contextualization relative to the large number of animals under husbandry in the U.S.
Conclusions:
- Compiling comprehensive national antimicrobial usage data in food animals presents considerable difficulties.
- Local usage programs are currently more effective than national data aggregation for promoting prudent antimicrobial use.
- Further development of clearly defined applications for national usage data is needed to enhance its utility.
Related Concept Videos
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...